Clinical Trial News and Research

RSS

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

New combination treatment provides better wound healing compared to SSGs alone

The use of meshed split skin autographs (SSGs) is a standard treatment for large, deep burns. However, serious scarring is often a result. In an effort to improve wound healing and reduce scarring, a team of researchers in The Netherlands tested a treatment technique on patients with serious, deep burns that employed SSGs along with autologous cultured proliferating epidermal cells (ECs) compared to SSGs alone.

3 Nov 2015

Patients with Down syndrome face additional challenge of early-onset dementia

Individuals with Down syndrome who survive into adulthood face the additional challenge of early-onset dementia, in which toxic amyloid plaques build up in the brain. The condition is strikingly similar to Alzheimer's disease, and as new work led by researchers at the Lewis Katz School of Medicine at Temple University shows, dementia in Down syndrome involves defects in a regulatory enzyme known as γ-secretase activating protein (GSAP), which also happens to malfunction in Alzheimer's disease.

3 Nov 2015

Common heart drug may halt progression of angiosarcoma

A common heart drug may stop the progression of angiosarcoma, a cancer of the inner lining of blood vessels, according to a study by researchers at Texas Tech University Health Sciences Center El Paso.

3 Nov 2015

CPFN, Cure CP raise funds to extend research on cerebral palsy

Will it one day be possible to cure cerebral palsy? Scientists working in a new field of study known as "regenerative medicine" think so. But support is needed to further the research, according to two non-profit organizations founded by parents of children with CP.

2 Nov 2015

Unique funding opportunity seeks countermeasures to protect healthy tissue from radiation exposure

Small U.S.-based companies developing countermeasures to protect healthy tissue from the effects of radiation exposures may be eligible for a unique funding opportunity offered through the National Space Biomedical Research Institute. NSBRI's Industry Forum is soliciting applications for its Space Medical and Related Technologies Commercialization Assistance Program (SMARTCAP).

31 Oct 2015

UofL evaluates safety of new therapeutic vaccine in women with HPV 16, 18 infections

Cervical cancer is the fourth most frequently occurring cancer in women. Human papillomavirus (HPV) is present in 99 percent of cervical cancers and is considered to be their cause. While most HPV infections will clear naturally within a few years, there has been no treatment available to hasten or improve the chance of natural eradication.

31 Oct 2015

Miriam Hospital enrolling local participants for Parachute implant clinical trial to treat heart failure

The Miriam Hospital is actively recruiting local participants for a U.S. clinical trial of the Parachute device for treating heart failure. The study is focused on determining if the new minimally invasive catheter-based device can slow the progression of heart failure, reduce repeat hospitalizations and death, and significantly improve quality of life for patients who experience enlargement of the left ventricle after a heart attack.

31 Oct 2015

ISCT launches publication and reference guide on Use of Unproven Cellular Therapies

The International Society for Cellular Therapy, the global society of clinicians, researchers, regulators, technologists, and industry partners dedicated to the translation of cellular therapy into safe and effective therapies to improve patients’ lives, today announces the launch of its publication and reference guide on the Use of Unproven Cellular Therapies.

31 Oct 2015

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the company’s first-in-class therapeutic vaccine candidate against HPV 16/18 infections.

31 Oct 2015

Xcelience announces grand opening of new headquarters in Tampa

Xcelience is proud to announce the grand opening of its new 71,000 square foot headquarters located at 4910 Savarese Circle in Tampa. The building houses preformulation and formulation development labs and suites, as well as analytical and stability services. The official ribbon cutting ceremony was attended by Florida Governor Rick Scott, Tampa Mayor Bob Buckhorn and other elected and non-elected officials.

31 Oct 2015

Specialized type of immunotherapy can boost survival from pancreatic cancer

A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy — even when used without chemotherapy or radiation — can boost survival from pancreatic cancer, a nearly almost-lethal disease, by more than 75 percent. The findings are so promising, human clinical trials are planned within the next year.

30 Oct 2015

Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that INOmax (nitric oxide) for inhalation has received regulatory approval in Australia and Japan for pulmonary hypertension in conjunction with heart surgery.

30 Oct 2015

New clinical trial on breast cancer may help treat and control disease

A new clinical trial at Sanford Health is exploring how genetic changes that occur during breast cancer might help health care providers better identify, treat and control the disease.

30 Oct 2015

Halozyme Therapeutics announces initiation of rivipansel Phase 1 clinical trial

Halozyme Therapeutics, Inc. today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics, Inc. and being developed by Pfizer Inc., using Halozyme's ENHANZE formulation.

30 Oct 2015

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.

30 Oct 2015

New studies raise important questions about impact of statin therapy on effectiveness of flu vaccines

A new pair of studies suggests that statins, drugs widely used to reduce cholesterol, may have a detrimental effect on the immune response to influenza vaccine and the vaccine's effectiveness at preventing serious illness in older adults. Published in The Journal of Infectious Diseases, the findings, if confirmed by additional research, may have implications for flu vaccine recommendations, guidelines for statin use around the time of vaccination, and future vaccine clinical trials in seniors.

29 Oct 2015

Rutgers Cancer Institute scientist leads phase III trial of FDA-approved viral melanoma therapy

The U.S. Food and Drug Administration has approved a viral melanoma therapy that was the focus of a phase III clinical trial led by Rutgers Cancer Institute of New Jersey Associate Director for Clinical Science and Chief Surgical Officer Howard L. Kaufman, MD, FACS.

29 Oct 2015

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer that can be difficult to treat.

29 Oct 2015

Clinical Trial News and Research

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

New combination treatment provides better wound healing compared to SSGs alone

Patients with Down syndrome face additional challenge of early-onset dementia

Common heart drug may halt progression of angiosarcoma

CPFN, Cure CP raise funds to extend research on cerebral palsy

Unique funding opportunity seeks countermeasures to protect healthy tissue from radiation exposure

UofL evaluates safety of new therapeutic vaccine in women with HPV 16, 18 infections

Miriam Hospital enrolling local participants for Parachute implant clinical trial to treat heart failure

ISCT launches publication and reference guide on Use of Unproven Cellular Therapies

First patient of U.S. phase 1 trial treated with Genticel’s GTL001 candidate for HPV 16/18 infections

Xcelience announces grand opening of new headquarters in Tampa

Specialized type of immunotherapy can boost survival from pancreatic cancer

Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

New clinical trial on breast cancer may help treat and control disease

Halozyme Therapeutics announces initiation of rivipansel Phase 1 clinical trial

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

New studies raise important questions about impact of statin therapy on effectiveness of flu vaccines

Rutgers Cancer Institute scientist leads phase III trial of FDA-approved viral melanoma therapy

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery